Key Statistics for ACOR
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (12/2013)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ACOR
- Net Income (M/USD)
Acorda Therapeutics Inc. is a biotechnology company that is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.
More Company Profile & Key Executives for ACOR
|Ron CohenPresident/CEO/Founder||Michael W RogersChief Financial Officer|
|Enrique J CarrazanaChief Medical Officer||Andrew R Blight "Andy"Chief Scientific Officer|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.